StockData
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc (MREO) company profile

MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 1/30
$0.29+0.01 (+5.39%)

Close on Nov 18, 2026Market cap $46.20MP/E –Yield –

About Mereo BioPharma

Pharmaceutical Preparations, SIC 2834

Mereo BioPharma Group plc is a biopharmaceutical company that develops therapeutics for rare diseases. The organization acquires drug candidates with prior development history from larger pharmaceutical corporations to advance clinical programs. Its principal late-stage clinical assets include setrusumab, a monoclonal antibody under evaluation for osteogenesis imperfecta, and alvelestat, an oral neutrophil elastase inhibitor designed for alpha-1 antitrypsin deficiency-associated lung disease. It also maintains vantictumab for autosomal dominant osteopetrosis Type 2. The company focuses on clinical-stage segments, serving patient populations with specialized medical conditions and collaborating with commercial biopharmaceutical partners.

The company conducts development activities across the United Kingdom and the United States, coordinating clinical trials through specialized clinical sites and contract research organizations. It partners with global life sciences firms, retaining commercial rights to specific programs in Europe and the United Kingdom. Mereo BioPharma Group plc maintains its principal executive offices in London, United Kingdom.

Summary of the business section of Mereo BioPharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Mereo BioPharma Group plc
Founded
2015
Headquarters
London, United Kingdom
Address
One Cavendish Place, Fourth Floor W1G 0QF
Phone
4403330237300
Employees
39, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
X0
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, United Kingdom

Stock & identifiers

Ticker
MREO
Exchange
Nasdaq
IPO date
Apr 24, 2019
Shares outstanding
798M, Aug 7, 2026
Public float
$368.47M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1719714
CUSIP
589492107
ISIN
US5894921072
FIGI
BBG00KFWZC67
Share class FIGI
BBG00KFWZCX7
LEI
213800U8JQHIJOS5AS09
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Denise Scots-KnightChief Executive Officer, Director808,921
Alexandra Hughes-WilsonSee Remarks134,483
Charles SermonGeneral Counsel219,061
John A. LewickiChief Scientific Officer92,826
Christine Ann FoxChief Financial Officer89,285
Pierre JacquetDirector–
Anders EkblomDirector37,940
Jeremy BenderDirector12,550
Daniel ShamesDirector–
Deepika PakianathanDirector1,825
Michael S. WyzgaDirector25,050
Annalisa JenkinsDirector–
Marc J. YoskowitzDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.73M-$1.96M$1.15M$56–
FY2024$3.16M$6.18M$1.28M$467–
FY2023$2.22M$5.45M$1.04M$308–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsOtherTotalvs. prior year
Dr. Denise Scots-Knight
Chief Executive Officer
$642.92K$2.00M$88.60K$2.73M-14%
Charles Sermon
General Counsel
$472.94K$635.48K$63.50K$1.17M-10%
Christine Fox
Chief Financial Officer
$444.67K$635.48K$52.53K$1.13M-10%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, Mereo had 39 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?